This presentation will focus on highlighting the rapidly growing AI movement as it impacts life science companies, calling out key legal developments and future product liability risks.

This is Part 6 of a six-part series. Part 1, 340B Program: Update on Current Developments is taking place on November 12, 2024, Part 2, How the toughened up, amended Fed. R. Evid. 702 has been faring is taking place on November 12, 2024, Part 3, New Rule 16.1 on MDLs is taking place on November 13, 2024, Part 4, PFAS Litigation in the MedTech Industry: Key Cases and Emerging Trends is taking place on November 13, 2024, and Part 5, Product Liability in Europe: Understanding and Planning for the EU’s Recent Complainant-Friendly Shift is taking place on November 14, 2024.

Each of these programs are presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas, and West Virginia. Applications for CLE credit will be filed in Delaware, Florida, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.